Edesa Biotech Adds Mechanically Ventilated Patients to Phase

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company

Related Keywords

Canada , California , United States , United Kingdom , Colombia , Poland , Toronto , Ontario , British , Gary Koppenjan , Linkedin , Edesa Biotech Inc , World Health Organization Covid , Twitter , Nasdaq , Exchange Commission , British Columbia Securities Commission , Securities Exchange , Contact Dermatitis Clinical Program , Clinical Program , Edesa Biotech , Acute Respiratory Distress Syndrome , World Health Organization , Par Nijhawan , Chief Executive Officer , Toll Like Receptor , Contact Dermatitis Severity Index , Static Global Assessment , Securities Act , Securities Exchange Act , British Columbia Securities , Sedesa , Biotech , Odds , Mechanically , Ventilated , Patients , Hase , Cards , Study ,